Oral Presentation Evaluation | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
|
In this episode, we are exploring the link between English spelling (orthography) and pronunciation - especially in words that end with the letters -MB (e.g. climb, numb, thumb etc.). Tom also shares some practical tips for improving your pronunciation in general. Happy listening! Cliquez ici pour télécharger la transcription. ------------------------- The Déclic Anglais Podcast est le podcast idéal pour progresser rapidement et efficacement en anglais. Avec un nouvel épisode tous les mardis, améliorez votre compréhension orale en anglais, débarrassez-vous de vos croyances limitantes sur l'apprentissage de l'anglais, découvrez des astuces pour ne plus faire les erreurs les plus fréquentes et apprenez-en plus sur la culture britannique ! ------------------------- Vous voulez pratiquer votre anglais à l'oral pour gagner en aisance et ne plus avoir peur de parler anglais ? Nous organisons deux fois par mois des cours de conversation en anglais en ligne : le lieu idéal pour parler anglais en toute décontraction dans un petit groupe motivé ! Prochaines dates, tarifs et inscriptions ici : https://www.declicanglais.com/ateliers ------------------------- Vous souhaitez aller plus loin et améliorer votre anglais sous tous ses aspects mais ne savez pas par où commencer, quelles ressources utiliser ? En vous abonnant au Déclic Anglais Club, ayez accès chaque mois à 4 nouvelles leçons exclusives pré-enregistrées pour nos membres, avec des exercices fun et interactifs basés sur les sujets abordés dans notre podcast. Ils vous permettront d'améliorer progressivement votre écrit, prononciation, compréhension en anglais. Et avec la version Boost, les deux cours de conversation mensuels sont inclus, ainsi qu'un cours d'anglais en groupe dont le sujet est choisi chaque mois par les membres du Club ! Infos, tarifs et inscriptions ici : https://www.declicanglais.com/presentation-declic-anglais-club ------------------------- Pour toute question ou remarque, n'hésitez pas à nous écrire à l'adresse [email protected] Notre site : www.declicanglais.com Retrouvez-nous aussi sur : Facebook / Instagram ------------------------ Soundtrack credits: Kevin Hartnell: Podcast Theme, album: CC BY-SA 4.0, Overlook Hotel Records. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.
Watch Reimagine Education and learn what's new with responsible AI in education >
Concise and clear speaking is an essential communication skill that employers value. According to the National Association of Colleges and Employers , approximately 96 percent of businesses view oral and written communication as an essential competency but only 42 percent of employees are proficient at these skills. In classrooms there is always someone presenting information. Whether students are engaging in discussion or giving reports, or educators are presenting new material or conferencing with students, presentation skills are critical.
Speaker Coach , a Microsoft Learning Accelerator , enhances both foundational and workplace skills. With a focus on public speaking, Speaker Coach uses innovative technology that automatically analyzes a speaker’s communication style and helps them present information more effectively. Whether they are a native speaker or an English Language Learner, any student will benefit from the practical feedback and custom reports that highlight areas of strength and ways to improve delivery. Speaker Coach helps students not only build critical skills, but they also develop confidence in their speaking abilities while practicing.
Intelligent, automatic help is one of many reasons why educators choose to use Speaker Coach with their students. Like other Learning Accelerators, Speaker Coach offers:
More importantly, Speaker Coach incorporates good pedagogy. Students oversee their own learning by following detailed, pragmatic feedback that can be applied to the task at hand: improving communication clarity and enhancing public speaking skills. The analysis also enables students to learn whenever and wherever it is most convenient without needing someone else to participate.
From individual support to following a curriculum pacing guide, educators have more teaching commitments than time to complete all that is required of them. That makes Speaker Coach a valuable tool for educators; it frees time for other tasks because students can use Speaker Coach’s automatic feedback instead of direct teacher intervention. Mike Thomas, Senior Digital Learning Analyst for Springfield Public Schools, believes that Speaker Coach and other Learning Accelerators positively impact teaching in his district:
School is 180 days at six hours a day, and we must prioritize what is being taught. By having these tools available, it puts less focus trying to always deliver. It gives students the ability to learn for themselves. With tools like Reading Progress, Immersive Reader, and now Speaker Coach, I think we can take that student empowerment to the next level.” Mike Thomas, Senior Digital Learning Analyst for Springfield Public Schools
Get feedback on your presentation
Speaker Coach in PowerPoint provides suggestions while a student speaks, and it delivers a tailored, final report that is packed with ways to improve their delivery. Using a computer’s camera and microphone, Speaker Coach analyzes key qualities of effective communication:
In addition to automatic, real-time suggestions while practicing, Speaker Coach generates a personalized report that can be used as a learning tool. Each report is customized to the speaking session, contains interactive feedback and analysis, and is privately shared so that students can securely review suggestions without the pressure of having another person listen and critique.
Rehearsal report summarizes your performance and provides actionable feedback
Because Speaker Coach automatically listens and analyzes multiple aspects of a presentation, students can use it at school or at home without someone else participating. Speaker Coach is like a teaching assistant who is always available and willing to offer constructive feedback in a judgement-free environment.
Students in Spring Public Schools in Springfield, MA have been using Speaker Coach to practice and prepare for classroom presentations. Educators are already seeing improvements in how ideas are communicated.
Speaker Coach is giving the students the confidence to be able to present in front of others and share their voice.” Melissa Zeitz, Digital Literacy and Computer Science Teacher for Springfield Public Schools
Rehearse with Speaker Coach
To start using Speaker Coach in PowerPoint:
Students and educators can also use Speaker Coach during scheduled Teams meetings and live events. The Teams integration delivers private speaking suggestions and guidance during roundtable discussions or while sharing content from a PowerPoint or Word Document. Unobtrusive tips appear at the top of the Teams window and are only visible to the speaker. When you leave the meeting, Speaker Coach generates a timestamped report with actionable insights for improving speaking clarity, word choice, inclusiveness, and information. This report lives inside of Teams and is available to review and compare over time or throughout the year.
Follow a few simple steps to use Speaker Coach in Teams for Education:
What are you waiting for? Say goodbye to standing in front of a mirror and talking to yourself. Instead, let Speaker Coach analyze your communication skills and reduce anxiety associated with public speaking.
Ai in education brings opportunity to life.
Watch Reimagine Education
Connect with us on social
Stay up to date with monthly newsletters from Microsoft Education.
Get inspired by stories from Microsoft Education customers.
Expand possibilities with educator training and professional development resources.
Connect with a Microsoft Education sales specialist to explore solutions for your school.
Discover a collection of resources to support a variety of educational topics.
SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present preclinical data from the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit, which will take place June 18–20, 2024 in Boston.
Details of the presentation are as follows:
Empowering Peptide Self Administration with Needle-Free Smart Capsules | |
Pioneering Devices to Increase the Reach of Peptide APIs | |
Wednesday, June 19, 2024 from 2:15 to 2:45 PM Eastern time | |
Sharat Singh, PhD, Head of Research, Biora Therapeutics, Inc. |
Dr. Singh will also participate in a panel discussion on June 19 at 8:45 AM titled “Uncovering Innovations in Peptide Drug Delivery & Formulation for Improved Bioavailability,” alongside representatives from Eli Lilly, Merck, and Novo Nordisk.
Selections from the presentation will be made available on the Biora Therapeutics website following the event.
About Sharat Singh, PhD Sharat Singh brings over 25 years of experience as a dynamic and innovative scientific leader to his role at Biora Therapeutics, where he is focused on development of the company’s ingestible drug-device combination product candidates. Dr. Singh previously held scientific leadership roles at Aclara Biosciences, Prometheus Laboratories, and Nestle Health Sciences, where he established partnerships with leading biotech/pharmaceutical companies and conducted multiple phase I/II clinical trials in both oncology and gastrointestinal disease. As Chief Scientific Officer at Prometheus Laboratories, Sharat worked on topical formulation of budesonide for both Crohn’s disease (marketed as Endocort) and ulcerative colitis. He is the key inventor of multiple platform technologies (CEER, ANSER, eTag, and LOCI) and has authored over 100 patents. In his academic career, Sharat conducted inter-disciplinary research as a postdoctoral fellow at Columbia University. He holds a PhD in Chemistry from IISc, Bangalore, and has authored over 100 manuscripts and presentations.
About the BioJet™ Systemic Oral Delivery Platform Biora's BioJet systemic oral therapeutics platform uses an ingestible capsule for needle-free, oral delivery of large molecules designed to achieve systemic bioavailability and replace injection for better management of chronic diseases.
The BioJet platform uses an ingestible device designed to transit through the digestive system and activate in the small intestine, where liquid jets deliver a drug directly into the small intestine for uptake into systemic circulation. The BioJet device is approximately the size of a multivitamin and is designed to autonomously deliver a wide range of large molecules, such as proteins, peptides, and nucleic acids, in liquid formulation at multi-milligram doses, without requiring complex reformulation.
Biora holds a comprehensive patent position for the BioJet systemic oral delivery platform, with approximately 12 issued patents and 31 pending applications that cover its delivery platform and methods for using the platform to treat a disease or condition in a patient using liquid jet delivery of a wide range of drugs.
About Biora Therapeutics Biora Therapeutics is reimagining therapeutic delivery. By creating innovative smart pills designed for targeted drug delivery to the GI tract, and systemic, needle-free delivery of biotherapeutics, the company is developing therapies to improve patients’ lives.
Biora is focused on development of two therapeutics platforms: the NaviCap™ targeted oral delivery platform, which is designed to improve outcomes for patients with inflammatory bowel disease through treatment at the site of disease in the gastrointestinal tract, and the BioJet™ systemic oral delivery platform, which is designed to replace injection for better management of chronic diseases through needle-free, oral delivery of large molecules.
For more information, visit bioratherapeutics.com or follow the company on LinkedIn or Twitter.
Safe Harbor Statement or Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, including statements concerning the progress and future expectations and goals of our research and development, preclinical and clinical trial activities, and partnering and collaboration efforts with third parties, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “anticipate,” “forward,” “believe,” “design,” “estimate,” “predict,” “potential,” “plan,” “target,” or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Such risks, uncertainties, and other factors include, among others, our ability to innovate in the field of therapeutics, our ability to make future FDA filings and initiate and execute clinical trials on expected timelines or at all, our ability to obtain and maintain regulatory approval or clearance of our products on expected timelines or at all, our plans to research, develop, and commercialize new products, the unpredictable relationship between preclinical study results and clinical study results, our expectations regarding allowed patents or intended grants to result in issued or granted patents, our expectations regarding opportunities with current or future pharmaceutical collaborators or partners, our ability to raise sufficient capital to achieve our business objectives, and those risks described in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC and other subsequent documents, including Quarterly Reports, that we file with the SEC.
Biora Therapeutics expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.
Investor Contact Chuck Padala Managing Director, LifeSci Advisors [email protected] (646) 627-8390
Media Contact [email protected]
Phase 2b Trial Demonstrated Statistically Significant and Clinically Meaningful Improvements Across Primary and all Secondary Endpoints up to 8 Weeks
TAK-861 is the First Oral Orexin Receptor 2 Agonist to Potentially Address the Underlying Pathophysiology of NT1
Safety Results Indicated TAK-861 is Generally Safe and Well Tolerated
Phase 3 Trials of TAK-861 to be Initiated in 1H FY2024
OSAKA, Japan and CAMBRIDGE, Massachusetts, June 3, 2024 – Takeda ( TSE: 4502/NYSE:TAK ) will present today positive results from its Phase 2b trial of TAK-861 in narcolepsy type 1 (NT1) as late-breaking data presentations at SLEEP 2024, the 38th annual meeting of the American Academy of Sleep Medicine and the Sleep Research Society. TAK-861 is an investigational oral orexin receptor 2 (OX2R) agonist and, based on the results, has the potential to provide transformative efficacy in addressing the overall disease burden in people with NT1. The randomized, double-blind, placebo-controlled, multiple dose trial, TAK-861-2001 ( NCT05687903 Go to https://classic.clinicaltrials.gov/ct2/show/NCT05687903?term=TAK-861&draw=2&rank=3 ), in 112 patients with NT1 demonstrated statistically significant and clinically meaningful improvements across primary and secondary endpoints, with efficacy sustained over 8 weeks of treatment.*
NT1 is a chronic, rare neurological central disorder of hypersomnolence caused by a significant loss of orexin neurons, resulting in low levels of orexin neuropeptides in the brain and cerebrospinal fluid. No currently approved treatments target the underlying pathophysiology of NT1. People with NT1 suffer from excessive daytime sleepiness (EDS), cataplexy (sudden loss of muscle tone), disrupted nighttime sleep, hypnagogic and hypnopompic hallucinations and sleep paralysis. These debilitating symptoms lead to a markedly reduced quality of life and can severely impact job performance, academic achievement and personal relationships. TAK-861 is designed to address the orexin deficiency in NT1 by selectively stimulating the orexin receptor 2.
The presentation highlights results from the Phase 2b trial including:
The primary endpoint demonstrated statistically significant and clinically meaningful increased sleep latency on the Maintenance of Wakefulness Test (MWT) versus placebo across all doses (LS mean difference versus placebo all p ≤0.001). Improvements were sustained over 8 weeks.
Consistent results were achieved in the key secondary endpoints including the Epworth Sleepiness Scale (ESS) and Weekly Cataplexy Rate (WCR), demonstrating significantly improved subjective measures of sleepiness and cataplexy (sudden loss of muscle tone) frequency versus placebo that were also sustained over 8 weeks.
The majority of NT1 patients in the trial were found to be within normative ranges for MWT and ESS by the end of the 8-week treatment period as a result of these sustained improvements.
The majority of the participants who completed the trial enrolled in the long-term extension (LTE) study with some patients reaching one year of treatment.
The trial also included additional exploratory endpoints that showed meaningful improvements in narcolepsy symptoms and functioning according to most participants. These data will also be presented in poster presentations at SLEEP and at future scientific congresses.
The dataset showed that TAK-861 was generally safe and well tolerated during the study, with no treatment-related serious treatment-emergent adverse events (TEAEs) or discontinuations due to TEAEs.
No cases of hepatotoxicity or visual disturbances were reported in the Phase 2b trial or in the ongoing LTE study. The most common TEAEs were insomnia, urinary urgency and frequency, and salivary hypersecretion. Most TEAEs were mild to moderate in severity, and most started within 1-2 days of treatment and were transient.
“In this trial, TAK-861's profile balanced efficacy and safety with the potential to establish a new standard of care for people with NT1,” said Sarah Sheikh, M.D., M.Sc., B.M., B.Ch., MRCP, Head, Neuroscience Therapeutic Area Unit and Head, Global Development at Takeda. “We are dedicated to investigating the full potential of orexin biology and advancing TAK-861 to late-stage clinical trials, with the ultimate goal of delivering a potential first-in-class treatment that can make a meaningful difference for patients.”
Based on these results, and in consultation with global health authorities, Takeda plans to initiate global Phase 3 trials of TAK-861 in NT1 in the first half of its fiscal year 2024. The Phase 2b data also supported the recent Breakthrough Therapy designation for TAK-861 for the treatment of EDS in NT1 from the U.S. Food and Drug Administration (FDA). Breakthrough Therapy designation is a process designed to expedite the development and review of a drug that is intended to treat a serious or life-threatening condition, for which preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapies on at least one clinically significant endpoint.
Takeda will be hosting a call to discuss these data this evening, June 3, at 7:30 p.m. CT for investors and analysts. Presentation slides and a virtual meeting link will be available here .
Additional presentations on TAK-861 will be shared during the SLEEP 2024 poster presentation session on Tuesday, June 4, from 10:00 to 11:45 a.m. CT, assessing function and health-related quality of life in individuals with NT1, as well as patient satisfaction with TAK-861 treatment. There is no change in Takeda’s full year consolidated forecast for the fiscal year ending March 31, 2025 (FY2024), announced on May 9, 2024.
Takeda is advancing the field of orexin therapeutics with a multi-asset franchise offering tailored treatments to unlock the full potential of orexin. Orexin is a key regulator of the sleep-wake cycle and is involved in other essential functions, including respiration and metabolism. TAK-861 is the leading program in this franchise. The company is also progressing multiple orexin agonists in patient populations with normal levels of orexin neuropeptides and other indications where orexin biology is implicated. This includes TAK-360, an oral OX2R agonist being investigated for narcolepsy type 2 and idiopathic hypersomnia, which recently initiated a Phase 1 trial and received Fast Track designation from the U.S. FDA, and danavorexton (TAK-925), an intravenously administered OX2R agonist being investigated in a Phase 2 trial in patients with moderate to severe obstructive sleep apnea undergoing general anesthesia.
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com .
* The topline results were announced on February 8, 2024, via a press release, “Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024."
Japanese media.
Yuko Yoneyama
[email protected]
+81 70-2610-6609
Rachel Wallace
For the purposes of this notice, “press release” means this document, any oral presentation, any question-and-answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov Go to https://www.sec.gov . Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.
This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.
IMAGES
VIDEO
COMMENTS
Research confirms that in order for ELLs to acquire English they must engage in oral language practice and be given the opportunity to use language in meaningful ways for social and academic purposes (Williams & Roberts, 2011). Teaching students to design effective oral presentations has also been found to support thinking development as "the ...
Guide to preparing oral presentations in English. Read the 5 steps to creating and delivering an English presentation with confidence, with downloadable assessment. ... Use spellcheckers to check the spelling of your slides and online dictionaries to listen to the pronunciation of words (such as the Cambridge Dictionary).
Voice, or vocal sound, is made when controlled air being exhaled from the lungs, passes over the vocal cords causing a controlled vibration. The vibrating air resonates in the body, chest cavity, mouth, and nasal passages. The vibrating air causes a chain reaction with the air in the room. The room's air, set in motion by the voice, is ...
The following page intends to give some useful tips and advice on improving pronunciation whilst giving a presentation. Get physical Do some 'warm-ups' to loosen up your mouth and your tongue before you speak. You can move and stretch your mouth, and repeat tricky words and sounds. Doing this will help you to overcome the physical 'stiffness' of the articulators and to speak fluently and clearly.
How to pronounce PRESENTATION. How to say PRESENTATION. Listen to the audio pronunciation in the Cambridge English Dictionary. Learn more.
If the words you need to know are long or complicated to pronounce, you could practise them before giving the presentation in English. One way to do this is by using a free Text to Speech programme (TTS). Insert sentences into the box which include the technical words and select a British English or American English voice if possible. Do not ...
Personal online tutoring. EnglishScore Tutors is the British Council's one-to-one tutoring platform for 13- to 17-year-olds. Giving an oral presentation as part of a speaking exam can be quite scary, but we're here to help you. Watch two students giving presentations and then read the tips carefully.
Delivering effective oral presentations involves three components: what you say ( verbal ), how you say it with your voice ( vocal ), and everything the audience can see about you ( visual ). For ...
Delivery. It is important to dress appropriately, stand up straight, and project your voice towards the back of the room. Practise using a microphone, or any other presentation aids, in advance. If you don't have your own presenting style, think of the style of inspirational scientific speakers you have seen and imitate it.
presentation frequency in english - B2 level of CEFR the word presentation occurs in english on average 24.1 times per one million words; this frequency warrants it to be in the study list for B2 level of language mastery according to CEFR, the Common European Framework of Reference.
Practice pronunciation of the word oral presentation with ELSA advanced technology and say oral presentation like Americans. Product Elsa Speak Speech Analyzer Redeem Promo Code Learn English ... Let's hear how you pronounce "oral presentation" oral presentation Tap then say the word Subscribe to Pro Access. Learn More About ELSA Pro Anybody ...
Here are 4 tips that should help you perfect your pronunciation of "oral presentation":. Break "oral presentation" down into sounds: [AW] + [RUHL PREZ] + [UHN] + [TAY] + [SHUHN] - say it out loud and exaggerate the sounds until you can consistently produce them.; Record yourself saying "oral presentation" in full sentences, then watch yourself and listen.
A large part of the impact of your presentation is made by your voice and body language, yet people generally focus their preparation on content. Make sure you allocate some time to considering and practising your speaking skills and body language. Voice. Good voice control and clear articulation are essential for an effective oral presentation.
Pronunciation of 'presentation' American English pronunciation British English pronunciation American English: pr i zɛnt e ...
Using these words in your introduction and throughout your presentation will help keep the audience engaged. For example, if giving a persuasive speech, speaking directly to the audience will have a better effect: "To help lessen the effects of global warming, the planet needs you.". Stop memorizing words.
Presentation skills are the abilities and qualities necessary for creating and delivering a compelling presentation that effectively communicates information and ideas. They encompass what you say, how you structure it, and the materials you include to support what you say, such as slides, videos, or images. You'll make presentations at various ...
20 Considerations and Strategies for Oral Presentations Introduction. Whether short, informal and require sharing of specific information within a small group, or more lengthy and structured, requiring visual aids and sharing on a specific topic to a larger audience, oral presentations are anxiety producing. ... pronunciation and structures ...
Yes, both are right. I don't know which is more common. But if you choose a pronunciation from a reliable dictionary, there should be no problem. If you chat with other speakers and hear them pronounce the word differently from you, then maybe you can change the way you pronounce it. Reliable dictionaries won't give you bad pronunciations.
An oral presentation is more than just reading a paper or set of slides to an audience. How you deliver your presentation is at least as important in effectively communicating your message as what you say. Use these guidelines to learn simple tools that help you prepare and present an effective presentation, and design PowerPoint slides that ...
ORAL PRESENTATION EVALUATION CRITERIA AND CHECKLIST. talk was well-prepared. topic clearly stated. structure & scope of talk clearly stated in introduction. topic was developed in order stated in introduction. speaker summed up main points in conclusion. speaker formulated conclusions and discussed implications. was in control of subject matter.
The correct pronunciation is extremely important especially when you are speaking English. The significant fact about pronunciation is that it is not something that you can learn but it's a physical skill that you need to practice and master regularly. Now, the question arises of how to master this. First of all, you need to identify your ...
The findings call for further research regarding what methods and techniques can be used to develop learners' pronunciation competence and English oral performance. Cite: Noor, L. (2021). Factors Affecting EFL Learners' English Pronunciation Competence and Oral Presentation Performance: A Study on Tertiary Level in Bangladesh.
ESL Oral Presentation Evaluation. Evaluates the key components of an effective oral presentation for ESL students. This is a holistic assessment. Rubric Code: R3ABX9. By amygporter. Draft. Public Rubric. Subject: Communication. Type: Presentation.
In this episode, we are exploring the link between English spelling (orthography) and pronunciation - especially in words that end with the letters -MB (e.g. climb, numb, thumb etc.). Tom also shares some practical tips for improving your pronunciation in general. Happy listening! Cliquez ici pour télécharger la transcription.
Concise and clear speaking is an essential communication skill that employers value. According to the National Association of Colleges and Employers, approximately 96 percent of businesses view oral and written communication as an essential competency but only 42 percent of employees are proficient at these skills.In classrooms there is always someone presenting information.
SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present preclinical data from the BioJet™ Systemic Oral Delivery Platform at the Next Gen Peptide Formulation & Delivery Summit, which will take place June 18-20, 2024 in Boston.
The presentations will also be available on Akero's website following the meeting. A late-breaking oral presentation will feature 96-week data from HARMONY, a Phase 2b study evaluating the efficacy and safety of EFX in patients with metabolic dysfunction-associated steatohepatitis (MASH), fibrosis stage 2 or 3 (F2-F3).
Biora is focused on development of two therapeutics platforms: the NaviCap™ targeted oral delivery platform, which is designed to improve outcomes for patients with inflammatory bowel disease ...
Additional presentations on TAK-861 will be shared during the SLEEP 2024 poster presentation session on Tuesday, June 4, from 10:00 to 11:45 a.m. CT, assessing function and health-related quality of life in individuals with NT1, as well as patient satisfaction with TAK-861 treatment.
Actinium Announces Results of Actimab-A + CLAG-M Combination Trial Highlighted in Oral Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting - read this article along with other careers information, tips and advice on BioSpace. Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) today ...